Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

COMT inhibitors and liver toxicity.

¹University of North Carolina at Chapel Hill School of Medicine, 27599, USA.

|January 9, 2001

Summary

Tolcapone, a COMT inhibitor, carries a risk of liver damage, leading to market withdrawal and warnings. Entacapone, another COMT inhibitor, has not shown similar hepatotoxicity risks in clinical or post-marketing studies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Classifying sex and strain from mouse ultrasonic vocalizations using deep learning.

PLoS computational biology·2020

Same author

The use of emollient therapy for ageing skin.

Nursing older people·2011

Same author

Isatin, regional distribution in rat brain and tissues.

Neurochemistry international·2010

Same author

Deriving probes from large-insert clones by PCR methods.

Current protocols in human genetics·2008

Same author

Identifying and treating plantar warts.

Nursing standard (Royal College of Nursing (Great Britain) : 1987)·2006

Same author

Insulin-treated diabetes and driving in the UK.

Diabetic medicine : a journal of the British Diabetic Association·2002

Area of Science:

Pharmacology
Hepatology
Drug Safety

Background:

Catechol-O-methyl transferase (COMT) inhibitors are used in treating Parkinson's disease.
Hepatotoxicity is a potential concern with certain medications.

Purpose of the Study:

To review and compare the hepatotoxicity profiles of tolcapone and entacapone.
To assess the safety of COMT inhibitors regarding liver function.

Main Methods:

Review of preclinical toxicity data.
Analysis of clinical trial results for tolcapone and entacapone.
Evaluation of post-marketing surveillance data for both drugs.

Main Results:

Tolcapone showed elevated liver enzymes in 1-3% of patients, leading to recommendations for liver monitoring and subsequent market withdrawal/warnings due to rare cases of liver failure.
Entacapone did not demonstrate an increase in liver enzymes compared to placebo, with no reported cases of drug-attributed liver failure.

Conclusions:

Tolcapone is associated with a significant risk of hepatotoxicity.
Entacapone has a favorable safety profile regarding liver function and does not require routine monitoring.

Related Experiment Videos